Intuitive Surgical (ISRG), the leader in robotic-assisted surgery, has seen its stock price decline approximately 30% in 2026, weighed down by weaker-than-expected guidance, intensifying competition, and elevated valuation multiples. The full-year performance is on track to be its worst since 2008. Although the long-term industry outlook remains expansive, near-term valuations still appear rich, and the path to recovery will likely take time. For long-term investors who can tolerate volatility and hold for a multi-year horizon, current price levels may present an entry opportunity, but they should be prepared for continued turbulence.
The medical technology company, best known for its da Vinci surgical robotic system, has long been favored by investors for its technological edge and high profit margins. However, the sustained decline this year has sparked divergent views on its prospects.
On the fundamental side, Intuitive Surgical’s recently disclosed financial data are not without bright spots. Second-quarter results released in July showed that global surgical procedure volume grew 16% year-over-year in the three months ended June, while revenue rose 19%, both maintaining double-digit growth rates. What truly unsettled investors, however, was the company’s full-year guidance: it expects da Vinci system procedure growth of 13.5% to 15.5% for the full year 2026. This range is lower than the actual performance in the second quarter and is viewed by the market as relatively conservative.
More concerning is that competitors are accelerating their entry into this high-margin arena. Healthcare giant Johnson & Johnson recently received regulatory approval for its Ottava robotic surgical system for use in a range of soft tissue procedures. Additionally, medical device company Medtronic secured related clearances for its Hugo robotic-assisted surgery system last year. Although Intuitive Surgical holds deep first-mover advantages in the industry, the increasingly competitive landscape could still erode its future market share, a prospect that worries investors.
Excessive valuation has long been a prominent issue for Intuitive Surgical’s stock. Over the past several years, the stock has traded at price-to-earnings ratios around 80 times, and even after a significant pullback, current valuations are still far from cheap. High multiples imply that the market has extremely high expectations for the company; once earnings growth fails to match valuation levels, the stock becomes vulnerable to additional pressure. Analysts believe that against the current backdrop of slowing growth and intensifying competition, investors are reassessing whether that premium is justified, and the stock may continue to face headwinds in the near term.
Long-Term Opportunities Coexist with Short-Term Pain
Looking at the industry landscape, the robotic-assisted surgery market still offers substantial room for growth, and Intuitive Surgical, as a pioneer in this field, has not lost its long-term development potential. However, investors may need to exercise greater patience, as the process of valuation correction and growth stabilization cannot be achieved overnight, and a rebound from the current downturn faces considerable obstacles.
